AutoGenomics said today that its Infiniti Neural Response Panel — a genomic test that gauges risk for opioid dependency — has been granted designation as a breakthrough device by the US Food and Drug Administration.
Intended for use by physicians as an aid in prescribing pain medication, the Infiniti panel uses an algorithm to detect and weigh 16 genetic mutations involved in brain reward pathways, which in turn affect risk of opioid use disorder.
